Lilly's 2nd-qtr rise hides coming challenges
US drug major Eli Lilly has reported solid financial results for the second quarter of 2008, but still decreased its financial guidance due to plant closure and staff lay-offs in preparation for the loss of patent for key drug, Zyprexa (olanzapine).
The firm's net income for the period from April 1 through June 30 rose 44% on the same period in 2007, reaching $958.8 million, or $0.88 per share. Worldwide sales increased 11% to $5.8 billion. Turnover for products that were launched this decade collectively grew by 21% to $1.8 billion and accounted for 35% of total revenues versus 32% for the second quarter of 2007.
Nonetheless, Lilly has decreased its financial guidance for the full-year 2008. The firm put this down to the strength of foreign currencies, but Global Insight analyst Gaelle Marinoni claimed the change was due to projected costs to be incurred for factory shut downs and staff redundancies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze